Although some genes identified here (e.g., CXCL3, MCM2, MELK) are known in CRC (Liao et al., 2025; Tian et al., 2024; Tang et al., 2022), our study distinguishes itself through a rigorous integrative bioinformatics workflow focused on druggable target discovery. This evidence concerns the gene MCM2 and colorectal carcinoma.